CagriSema Phase 3: What to Expect and When
CagriSema (cagrilintide + semaglutide) is the most-watched obesity-pharmacology combination in Phase 3 trials. Here's what the program is testing, what the Phase 2 data suggests we'll see, when readouts are expected, and what approval would mean.
The 60-second version
CagriSema combines cagrilintide (long-acting amylin analog) with semaglutide in fixed combination. Phase 3 REDEFINE program is the largest active obesity-pharmacology development effort by Novo Nordisk. Phase 2 showed additive weight loss over semaglutide alone. REDEFINE Phase 3 readouts expected through 2025-2026, with potential approval 2026-2027. If approved, CagriSema would be one of the first fixed-combination obesity medications with two distinct mechanism arms and could shift practice toward combination therapy.
Key takeaways
- CagriSema combines cagrilintide (amylin) with semaglutide (GLP-1) in fixed combination.
- Phase 2 demonstrated additive weight loss over either component alone.
- Phase 3 REDEFINE staggered through 2025-2026; approval likely 2026-2027.
- Expected weight loss: 20-25%+ at 68 weeks, comparable to or exceeding tirzepatide.
- First fixed-combination obesity medication with two distinct mechanism arms.
- Initial Phase 3 readouts showed smaller magnitudes than optimistic predictions.
- Current GLP-1 patients have no reason to wait — staying on existing therapy is appropriate.
The mechanism: why GLP-1 + amylin matters
Semaglutide is a GLP-1 receptor agonist. Cagrilintide is a long-acting amylin analog. Different receptor systems and different appetite-regulation circuits: GLP-1 works through GLP-1 receptors in hypothalamus and brainstem; amylin works through calcitonin receptor heterodimers in distinct neural pathways. Combination logic: different appetite circuits should produce additive effects, with smaller side-effect amplification than receptor-stacking within a single molecule.
What Phase 2 showed
Frias et al., Lancet 2023: CagriSema 2.4 mg + 2.4 mg combination vs. cagrilintide alone, semaglutide alone, or both. CagriSema produced HbA1c reductions superior to either component alone. Weight loss significantly greater than either component. Additive effect on body weight approximately what theory predicted. Side effect profile manageable. Result supported development hypothesis: combination is genuinely additive, not redundant.
The Phase 3 REDEFINE program
REDEFINE 1: CagriSema vs. placebo and active components in adults with obesity without diabetes. REDEFINE 2: CagriSema in obesity with T2D. REDEFINE 3: Cardiovascular outcomes trial — long-term clinical outcomes including MACE. Additional trials in older adults, post-bariatric, etc. Among the largest active obesity drug development efforts. Readouts staggered through 2025-2026.
What we're likely to see
Weight loss magnitude: Likely 20-25%+ at 68 weeks, comparable to or exceeding tirzepatide. Realistic expectation: between tirzepatide and retatrutide magnitudes.
Glycemic control: Strong HbA1c reduction.
Side effect profile: Likely similar to GLP-1 monotherapy with modest additional GI effects from amylin.
Cardiovascular outcomes: Likely positive based on semaglutide SELECT foundation; cagrilintide may add modest CV benefit.
Renal outcomes: Likely positive in T2D-CKD, building on FLOW.
When approval might happen
Phase 3 readouts: staggered through 2025-2026. NDA submission: 6-12 months after positive readouts. FDA review: 10-12 months standard. Expected approval: 2026-2027, potentially into 2028.
Initial Phase 3 readouts from late 2024 showed weight loss magnitudes lower than some analyst expectations — additive effect was real but smaller than most optimistic predictions. This isn't unusual for combinations and doesn't prevent approval, but has affected market expectations.
What approval would mean
First fixed-combination obesity medication with two distinct mechanism arms. Likely first-line for some profiles (plateau on GLP-1 monotherapy, maximum effect needed). Competitive pressure on tirzepatide. Premium pricing likely. Validation of combination paradigm beyond single-molecule receptor-stacking.
Positioning vs. competition
2026-2027 landscape: tirzepatide (established dual-agonist, ~21%), retatrutide (Phase 3, ~24%), CagriSema (Phase 3 readouts pending), bimagrumab + GLP-1 (Phase 3). Each represents a different strategic approach to deepening treatment beyond first-generation GLP-1 monotherapy.
Practical implications for current patients
Doing well on current therapy: stay the course. Plateaued or undertreated: CagriSema may be a future option worth tracking. Insurance-restricted: CagriSema pricing and coverage will be question marks. Starting therapy: standard first-line semaglutide or tirzepatide remains appropriate.
Frequently asked questions
Will CagriSema produce more weight loss than tirzepatide?
Possibly, but not by a dramatic margin. Phase 3 magnitudes tracking toward 20-25%+, comparable to or somewhat exceeding tirzepatide's 21%.
Can I get the combination now off-label?
Pramlintide + semaglutide as off-label combination is possible with a willing prescriber. Cagrilintide isn't yet approved.
Should I wait for CagriSema before starting weight-loss therapy?
No. Waiting is the wrong move. Current options are highly effective and approved. Start now and possibly switch later.
Will CagriSema be more expensive than tirzepatide?
Probably yes, given combination-product positioning. Specialty-pharmaceutical-tier pricing expected.
References
- Frías JP, et al. Cagrilintide 2.4 mg with semaglutide 2.4 mg in T2D. Lancet. 2023;402(10403):720-730. https://pubmed.ncbi.nlm.nih.gov/?term=cagrisema
- Lau DCW, et al. Once-weekly cagrilintide for weight management. Lancet. 2021;398(10317):2160-2172. https://pubmed.ncbi.nlm.nih.gov/34798033/
We update articles as new trials publish and the evidence base evolves. Last reviewed: May 2026.